TNFRSF17 and plasma cell myeloma: Notably, the ciltacabtagene autoleucel (cilta‐cel) CAR‐T, an FDA‐approved nano antibody product, was used to treat recurrent and/or refractory multiple myeloma (R/RMM) in adults by targeting mature B cell antigens (BCMA) through the recognition of two distinct epitopes of BCMA simultaneously using its dual binding domain.